Reporting of adverse events ONLY

Patients should always seek the advice of a doctor or pharmacist in case of adverse events.

If you wish to report an adverse event to ELC Group s.r.o., please find the contact information below:

00420 224 910 672

(from 09.00-17.30 CET)

00420 723 694 460

(non-stop 24/7)

To contact us about any other issue please call:

+420 22 491 0000or our regional offices.

Hlášení nežádoucích príhod

Pacienti by meli vždy požádat o radu svého lékare nebo lékárníka v prípade výskytu nežádoucích príhod.

Pokud chcete nahlásit nežádoucí príhodu spolecnosti ELC Group s r.o., prosím využijte kontaktních údaju níže:

00420 224 910 672

(09.00-17.30 CET)

00420 723 694 460

(non-stop 24/7)

Pro záležitosti, které se netýkaji farmakovigilance, kontaktujte prosím recepci:

+420 22 491 0000 nebo naše další pobočky.

ELC Group Appoints Dr. Siddharth Chachad as Head of Global Clinical Development and Medical Affairs

Internationally acclaimed clinical pharmacologist joins global regulatory affairs specialist in key management post

Cambridge, UK, 20 August, 2014 – ELC Group, one of the fastest-growing providers of regulatory affairs, today announces the appointment of internationally acclaimed clinical pharmacologist Dr. Siddharth Chachad as Head of Global Clinical Development and Medical Affairs.

A member of the UK Faculty of Pharmaceutical Medicine, Dr. Chachad is an expert in the design and execution of pre-clinical and clinical development programme for drug products across dosage forms and therapeutic categories. Dr. Chachad has gained considerable career experience in the delivery medical services, medico-regulatory affairs and clinical development, and has worked across global clinical development strategy and operations of generics, new drugs and biosimilars. Dr. Siddharth’s extensive expertise covers all phases of clinical studies, including pre-clinical, pharmacodynamic studies, bioequivalence, PK in patients and full-blown clinical efficacy and safety studies.

“The appointment of Dr. Siddharth Chachad comes at a pivotal time for ELC Group,” said Marco Rubenstein, CEO of ELC Group. “Having been instrumental in the development of successful product registration strategies, I have no doubt that Dr. Siddarth will prove an exceptional leader of our Global Clinical Development and Medical Affairs team.”
Dr. Chachad added: “I am excited to be joining ELC Group and bringing my experience of Clinical Development and Medical Affairs to what is already a world-class team in this area.”

A renowned speaker at numerous clinical research and pharmacovigilance conferences, Dr. Chachad has authored over 25 publications.